TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percent Drinking Days (%DD)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of cranial flap fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants by ESA Types at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0 - t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0 - ∞
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Culture-Confirmed Influenza Illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Occurrence of complications of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Proportion of participants with solicited and treatment-related unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with serious adverse events (SAEs) related to investigational product
Endpoint domain: Adverse events/effects
Primary endpoint: Serum concentration of each antibody in each group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic value of EBUS image features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PTSD Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decisional conflict regarding prostate cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intention to be screened for prostate cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CTC phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival in incident hemodialysis patients
Endpoint domain: Mortality/survival
Primary endpoint: Pain VAS (Visual Analog Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Mountain Sickness (AMS) severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wear of polyethylene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-term birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative 3-month incidence of symptomatic venous thromboembolic events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in re-epithelization rate with autologous epidermal cell suspension graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in re-epithelization rate with silver sulfadiazine ointment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Absolute Change in CD4 Cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in CD4 Cell Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in Slope of CD4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Th2/Th1 ratio upon enrollment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Th2/Th1 ratio on Day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Th2/Th1 ratio on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Resolution of Initial Flare and Absence of New Flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients self-referring for recurrence of diabetic foot-ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Likert Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gait performance at CvMob
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posture analysis at CvMob
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Platelet Inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of subjects with complete occlusion on angiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of subjects with ipsilateral major stroke or neurologic death
Endpoint domain: Adverse events/effects
Primary endpoint: Parameters D* and f in healthy white matter or gray matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month Progression-free Survival Rate (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Sore throat after intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hoarseness after intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Change of log10 HIV-1 RNA Copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mania Acute Rating Scale (MACS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute Graft-versus-Host Disease (GVHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hearing aid usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the radioactivity time curve from zero to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the radioactivity time curve from time 0 to last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak radioactivity (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Treatment Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Walking Time Tolerated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-polypectomy major bleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in General Help Seeking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for Autoinjector A Versus Autoinjector B
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak Workload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Who Achieve Body Weight Reduction More Than or Equal to 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Self-Care Inventory (SCI)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change From Baseline in Frontotemporal Dementia Rating Scale (FTDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of partial and complete biochemical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Success rate of abortion
Endpoint domain: Mortality/survival
Primary endpoint: Interval to abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to chemotherapy, if there is residual disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in clinical risk factors for cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean change in serum aminotransferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meibum Gland Secretion Score (MGS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical characteristics of COVID-19 patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory characteristics of COVID-19 patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging characteristics of COVID-19 patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in T2 relaxation time of skeletal muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Detection of pain, at admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of a primipaternity factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDTRS 5% Contrast Sensitivity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in EDTRS 5% Contrast Sensitivity (LogMAR Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Who Required Intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in Bispectral Index after sugammadex injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of clinical signs of awakening after sugammadex injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative variation in apoptotic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Target Low-Density-Lipoprotein Cholesterol (LDL-C) Levels of ≤100 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Discontinued the Study due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of sorafenib tosylate
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of OK432 sclerotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU transfer and ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in absolute lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: changes in creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: secondary bacterial infections
Endpoint domain: Adverse events/effects
Primary endpoint: Montgomery Asberg Rating scale - MADRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic improvement by National Early warning score (NEWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of ICU admissions or deaths
Endpoint domain: Mortality/survival
Primary endpoint: Change in Visceral Adipose Tissue Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in baseline overall dry skin score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in baseline corneometer readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in baseline sebumeter readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Treatment Responders Based on the Numerical Rating Scale-Pain (NRS-Pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary markers of ATP utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cell injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Positive Mood/Affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Negative Mood/Affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of treatment emergent events
Endpoint domain: Adverse events/effects
Primary endpoint: Abnormal clinical laboratory findings
Endpoint domain: Adverse events/effects
Primary endpoint: Abnormal electrocardiogram findings (QT and QTc intervals)
Endpoint domain: Adverse events/effects
Primary endpoint: HIV DNA and RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of germline pharmacogenetic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eligible pregnant women with CD4 enumeration prior to 26 weeks gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of eligible women with HAART initiation prior to 30 weeks gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to use the transplanted limb in activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent change in Eczema Area and Severity Index (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Depression Symptom Checklist 20 (SCL-20) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anesthetic depth monitoring for sedation (ADMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bladder and bowel function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in sexual function and activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of drug resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Tooth discoloration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With ASAS-20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants With ASAS-40 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Connected Speech Test (CST) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mid expiratory flows
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-education knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Sino-Nasal Outcome Test Scores (SNOT-22)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of NBI in predicting radicality of polypectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Collection of tissue and body fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability of Coil to produce MRI images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting energy expenditure in kilocalories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat mass in kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat-free mass in kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neurodevelopmental Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sulfasalazine Steady State Maximum Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sulfasalazine Area Under the Concentration-time Profile (AUCtau) at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-aminosalicylic Acid (5-ASA) Steady State Maximum Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of lens opacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lens thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation Exposure (Dose-Length-Product)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Annualized Costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Left ventricular infarct size by SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular diastolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Virtual Reality Satisfaction Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Wong-Baker Faces Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Postpartum Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recurrence rate at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: patient-centered communication
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: LATCH score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sucking time of babies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feeding type of babies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of LDE225
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of SSB Consumption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence and severity of hepatic transaminases and bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ECG-documented Ventricular Fibrillation or Symptomatic Sustained Ventricular Tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment of vital signs, laboratory variables and ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving >50% reduction in fecal incontinence episodes/weeks at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving >50% reduction in fecal incontinence episodes/weeks at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hop Test Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Y-Balance Test Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Auditory Awakening Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Interrogation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to optimum treatment following diagnosis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Atrial Fibrillation Dominant Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality at one-year of follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Continuous Abstinence From Smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Load of traumatic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum 8-iso-PGF2α
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival status at one year
Endpoint domain: Mortality/survival
Primary endpoint: Total meat and animal product consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression of Change (CGI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dependence on analgesic drugs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post discharge hospital readmission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in autonomic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of biomarkers in female patients with LUTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25-Hydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Parathyroid Hormone (iPTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: aerobic and anaerobic enzyme levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-Xa peak level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of clinical registries related to diabetes mellitus II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of clinical registries related to dyslipidemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of clinical registries related to hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of clinical registries related to cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of use of services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use